Repros Therapeutics — Investor Presentation (September 2013)
37 slides from Repros Therapeutics's investor presentation, Sep 27, 2013
Slide 1: Developing clinical stage small molecule therapeutics for hormonal and reproductive disorders
Developing clinical stage small molecule therapeutics to treat hormonal and reproductive system disorders
Slide 2: Repros Disclaimer
Repros Disclaimer Any statements made by the Company that are not historical facts contained in these slides (or in any oral accompanying discussion) are forward - looking statements that involve risks and uncertainties that could cause actual results to differ materially from the results expressed
Slide 3: Investment Highlights
Investment Highlights • Focused strategy: small molecule therapeutics for reproductive disorders • Two late stage clinical programs each with +$1B sales potential • Androxal ® : PHASE 3 (SPA) oral treatment for Low Testosterone – Patented and pending patent’s life to the mid 2020’s – Growing +$2B ma
Slide 4: Testosterone Market and Androxal Overview
Testosterone Market and Androxal Overview • US market for low testosterone exceeds $1.5 billion • Only approved non invasive therapies are hormone replacements • Repros believes 85% of hypogonadal men experience low T due to an endocrine disorder – These men have functional but un - stimulated teste
Slide 5: Who are the men using testosterone?
Who are the men using testosterone? European Male Aging Study Distribution and Selected Characteristics of Men Ages 40 - 79 (Tajar et al) 0 10 20 30 40 50 60 70 80 90 100 Eugonadal Secondary Hypogonadal Primary Compensated Hypogonadism % of Subjects Age: 58.5 (10.7) BMI: 27.3 TT: 513.4 ng/dL LH: 5.2
Slide 6: Androxal Exhibits Patient Reported Effects Equivalent to Androgel
Androxal Exhibits Patient Reported Effects Equivalent to Androgel ZA - 003 Type C FDA Meeting Q4 - ’07 Unacceptable Endpoint for Phase 3 0 5 10 15 20 25 30 Androxal Androgel IIEF Score Baseline 6 mos. Androxal approaches statistical significance p=0.08 compared to baseline and Androgel change 0 2 4
Slide 7: Type C Meetings Lead to SPA on 1st Pass
Type C Meetings in 1Q10, 3Q10 & 2Q12 ZA - 203 Lead to SPA on 1 st Pass Repros Convinces FDA Exogenous T Suppresses Pituitary Hormones and Testicular Function 0 2 4 6 8 10 12 14 12.5 mg 25 mg PL Testim FSH Treatment Effect of Treatment on Median FSH p versus Testim Before After p<0.00001 p=0.0004 0 1
Slide 8: FDA Accepted Phase 3 Protocols Under an SPA
FDA Accepted Phase 3 Protocols Under an SPA Goal to Submit NDA Mid 2014 • Phase 3 pivotal studies conducted under SPA – 2 identical trials (BMI > 25, Age ≤ 60) • ZA - 301 152 subjects (114 on Androxal, 38 on placebo) • ZA - 301 181 subjects ( 134 on Androxal, 47 on placebo) – Men with morning T<300
Slide 9: Two Pivotal Studies Meet FDA SPA Prescribed Endpoints
Two Pivotal Studies Meet FDA SPA Prescribed Endpoints Highly Statistically Significant and Clinically Relevant Outcome in Restoring Testicular Function in Secondary Hypogonadal Men 0 10 20 30 40 50 60 70 80 90 Study ZA-301 Study ZA-302 % of Subjects in Normal Range for 24 Hour - Avg T Androxal Place
Slide 10: Two Pivotal Studies: Non-inferior to Placebo Regarding Spermatogenesis
Two Pivotal Studies Meet FDA SPA Prescribed Endpoints Non - inferior to Placebo Regarding Effects on Spermatogenesis in Secondary Hypogonadal Men 0 10 20 30 40 50 60 70 80 90 <50% 50-150% >150% % of Subjects Avg. Sperm Concentration as a % of Baseline after 12 Week Treatment Androxal 301 Androxal 30
Slide 11: Summary of Days of Abstinence by Change in Sperm Concentration
Summary of Days of Abstinence by Change in Sperm Concentration Status Days of Abstinence ≥ 50% Decrease in Sperm Concentration < 50% Decrease in Sperm Concentration N 17 134 Mean (Std) 2.7 (0.9) 4.0 (3.2) Median 2.5 3.5 (Min, Max) (2.0, 5.0) (2.0, 30.0) 95 % CI (2.2, 3.1) (3.4, 4.5) Wilcoxon P - val
Slide 12: Ejaculation Frequency Reduces Sperm Numbers
Ejaculation Frequency Reduces Sperm Numbers (n=12 subjects (age 18 - 25) 0 10 20 30 40 50 60 70 80 90 100 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 % of Baseline Total Sperm Count Days Fertility and Sterility, Levine et al Vol.5, No. 5, May 1986
Slide 13: ZA-302 Adverse Events by Incidence
ZA - 302 Adverse Events (≥ 2 %) by Incidence Preferred Term Androxal 12.5 mg (n=116) N (%) Androxal 25 mg (n=18) N(%) Androxal 12.5 & 25 mg (n=134) N(%) Placebo (n=47) N(%) Overall (n=181) N(%) No adverse events 73 (62.9) 14 (77.8) 87 (64.9) 31 (66.0) 118 (65.2) At least one adverse event 43 (37.1)
Slide 14: ZA-300 Population Summary
ZA - 300 Population Summary • 499 Subjects Enrolled – 12.5 mg (n = 234) – 25.0 mg (n = 265), these subjects experienced a morning Testosterone less than 450 ng/dL and were up - titrated • Race/Ethnicity – 84.5% Caucasian (includes Hispanic ethnicity) – 11.3% African American – 4.2% Other • Mean Age
Slide 15: ZA-300 Testosterone Response Six Month Safety Study
ZA - 300 Testosterone Response 500 Subject Six Month Safety Study • Over 90% of subjects had a maximum morning Testosterone above 300 ng/dL • Almost 67% of subjects had a maximum morning Testosterone above 450 ng/dL • 53% of subjects were up - titrated (T < 450 ng/dL) • Only 3 subjects experienced a
Slide 16: ZA-300 Adverse Events by Incidence
ZA - 300 Adverse Events (≥ 2 %) by Incidence PREFERRED TERM ANDROXAL 12.5 MG (N=234) N (%) ANDROXAL 25 MG (N=265) N (%) OVERALL (N=499) N (%) UPPER RESPIRATORY TRACT INFECTION 29 ( 12.4) 29 ( 10.9) 58 ( 11.6) HEADACHE 15 ( 6.4) 18 ( 6.8) 33 ( 6.6) MUSCLE SPASMS 9 ( 3.8) 11 ( 4.2) 20 ( 4.0) FATIGUE 1
Slide 17: ZA-300 SAEs
ZA - 300 SAEs Subject Number Dose Event Term Relationship 06-042 12.5 mg Hypotension/Bradycardia post Knee Replacement Surgery Not Related 07-052 12.5 mg Gallstone/Cholecystectomy Not Related 12-071 12.5 mg Biliary Colic/Common Bile duct dilatation Not Related 14-080 12.5 mg TIA Not Related 15-003 1
Slide 18: Phase III Androxal Program Status
Phase III Androxal Program Status NDA Target: Mid 2014 Study Target Enrollment Study Duration Subjects Screened Subjects Enrolled Projected Full Enrollment Top Line Results ZA - 300 Safety 500 6 months 1288 (30 sites) 499 Completed Generally well tolerated ZA - 301 Pivotal 152 3 months (+ 6 weeks) 5
Slide 19: How do we maximize shareholder return?
How do we maximize shareholder return? • All Repros Assets are Unencumbered • Androxal asset should be +90% de - risked during Q1 - ’14 • Androxal should open T treatment into primary care – Outside the scope of Repros capability • Measured launch of Androxal into specialty space • KOL board establi
Slide 20: Market Analysis: Total Prescriptions for Hormone Therapies
Market Analysis Total Prescriptions for Hormone Therapies Across All MDs Across all physician specialties, androgen hormone prescriptions have been growing more than 20% per year and now total almost 7.5 million per year. 20 0.0K 50.0K 100.0K 150.0K 200.0K 250.0K 300.0K 350.0K 400.0K 450.0K 500.0K T
Slide 21: Preliminary Sales Footprint: FT and PT Business Rules
Preliminary footprint : 41 FT and 3 PT Business Rules Workload Assumptions : ▪ 6 calls per day ▪ FT: 210 working days ▪ PT: 137 working days ▪ Territory Workload: 1,260 calls for FT ▪ Territory Workload: 822 calls for PT Design Assumptions : ▪ Territory Radius: ~150 miles Frequency Assumptions: ▪ D1
Slide 22: Scenario Overview: Original Endo Only vs. Endo & Uro
Scenario Overview Original Endo Only vs. Endo & Uro Scenario In the original analysis, Quintiles developed a scenario covering 90% of endo TRXs. Quintiles has detailed a new scenario covering deciles 80% of endo and uro TRXs. Original Endo Only Scenario Scenario 1: 90% Endo TRX Coverage Parameter De
Slide 23: New Endo & Uro Scenario Expense Budget
NOTES : 1. The prior assumptions and caveats under the original scenario remain. 2. We believe that the only material change to these expenses are related to the size of the Sales Team. We have kept other expenses the same. Commercial Function Pre - Launch (Launch Minus 18 Months) Launch Year Launch
Slide 24: New Endo & Uro Scenario Forecast
New Endo & Uro Scenario Forecast Based on conservative TRX growth assumptions, peak market share at 21%, and a slight price premium, Androxal generates nearly $150 million per year. Q4 2013E Q1 2014E Q2 2014E Q3 2014E Q4 2014E Q1 2015E Q2 2015E Q3 2015E Q4 2015E Q1 2016E Q2 2016E Q3 2016E Q4 2016E Q
Slide 25: Testosterone Levels Age-related Changes
Testosterone Levels Age - related Changes EMAS, European Aging Male Study; FHS, Framingham Heart Study; MrOS, Osteoporotic Fractures in Men Study. Bhasin S, et al. J Clin Endocrinol Metab . 2011;96(8):2430 - 2439. Total Testosterone, ng/dL 20 - 29 30 - 39 40 - 49 50 - 59 60 - 69 70 - 79 1000 800 200
Slide 26: Androxal Exhibits Unique Profile with Numerous Advantages
Androxal Exhibits Unique Profile with Numerous Advantages vs Approved Hormone Replacement • The Androxal Advantages – Oral – Not controlled substance, cannot be abused – No transference risk – Restores normal function (no loss of testicular function) – Does not develop dependency – Avoids withdrawal
Slide 27: Projected Income Through 2016
Projected Income Through 2016 (in millions) 2014 2015 2016 Total Net Revenue - $9.0 $92.0 $101.0 Expenses: R&D Androxal $7.5 - - $7.5 R&D Proellex $8.0 $15.5 $14.5 $38.0 Sales & Marketing $2.0 $15.0 $24.0 $41.0 General Corporate $6.0 $10.0 $11.5 $27.5 Net Income (EBITDA) $(23.5) $(31.5) $42.0 $(13.0
Slide 28: Proellex for Uterine Fibroids and Endometriosis
Proellex for the Treatment of Uterine Fibroids and Endometriosis • Over 30 million women of reproductive age in the US afflicted with symptomatic uterine fibroids or endometriosis • Over 300,000 hysterectomies performed every year in the US to treat these two disorders • No acceptable chronic therap
Slide 29: An Effective Dose of Proellex Stops Menstruation in Majority of Women
An Effective Dose of Proellex Stops Menstruation in Majority of Women 0 10 20 30 40 50 60 70 80 90 100 1 mg 3 mg 6 mg 9 mg 12 mg 25 mg 50 mg % of Women with Induced Amenorrhea Proellex induced amenorrhea Mimics early follicular phase Without progesterone 20
Slide 30: Proellex Eliminates the Pain and Need for Analgesics in Endometriosis
Proellex Eliminates the Pain and Need for Analgesics to Control the Pain of Endometriosis 0 10 20 30 40 50 60 70 Placebo Proellex 25mg Proellex 50 % of Baseline p - value versus placebo 25 mg = 0.001 50 mg = 0.017 55.5 22.2 13.6 0 10 20 30 40 50 60 70 80 90 100 Placebo 25mg Proellex 50mg Proellex %
Slide 31: ZPE-202 Phase 2 Endometriosis Study
ZPE - 202 Phase 2 Endometriosis Study • 90 subject double blind placebo controlled study balanced between placebo, 6 and 12 mg oral Proellex – Subject population (confirmed endometriosis) • Severe endometriosis as determined by BBSS score • Requiring narcotics or prescription analgesics to control e
Slide 32: Vaginal Proellex to Eliminate the Need for Hysterectomy
Vaginal Proellex to Eliminate the Need for Hysterectomy in Most Situations • Initial Phase 2 study tested four doses of vaginal administration in the treatment of uterine fibroids completed – Assess reduction of fibroid size and elimination of symptoms – Top line data reported • FDA requires additio
Slide 33: Systemic Exposure to Oral Proellex Varies in a Dose Dependent Manner
Systemic Exposure to Oral Proellex Varies in a Dose Dependent Manner Significant reduction in exposure via vaginal delivery 0 200 400 600 800 1000 1200 1400 1600 1800 12 mg vaginal 1 mg 3 mg 6 mg 9 mg 12 mg 25 mg 50 mg Concentration (ng/ml) Combined Cmax for Telapristone and Primary Metabolite Liver
Slide 34: Vaginal Proellex (ZPV-200) PBAC Scores Over Time
Vaginal Proellex (ZPV - 200) PBAC Scores Over Time PBAC Score >80 = menorrhagia 26 12 dose significantly improves excessive menstrual bleeding due to fibroids
Slide 35: ZPV-201 Ext. Proellex Open Label Update
ZPV - 200 Ext. Proellex Open Label Update (12mg dose) 0 10 20 30 40 50 60 70 80 90 100 Baseline End of 1st Cycle End of 2nd Cycle % of Initial Volume 12mg in initial treatment (n=15 fibroids) 3 or 6mg in initial treatment (n=14 fibroids) Paired Comparison for Subjects Dosed at 12 Throughout Study •
Slide 36: Proellex Clinical Goals
Proellex Clinical Goals • Enter Phase 3 • Uterine Fibroids: Second half 2014 • Endometriosis: Fourth Quarter 2014 • Submit 1 st Proellex NDA • Second Half 2016 • Pre - clinical complete • Phase 1 complete except TQtc
Slide 37: Financial Summary
Financial Summary • Cash and equivalents (as of 9/20/13) $82.0 M • Cash runway: 2016 – Both drugs’ NDAs filed – Anticipate Androxal approved and launched • Current shares outstanding: 23.0 M shares – Warrants Outstanding – Series A – 877,137 (purchased in unit deal @ $2.45); Series B – 810,109 @ $2.
Repros Therapeutics — Investor Presentation (September 2013) on 6ix